After passing on an option to buy Acetylon in the summer, Celgene has come back with a deal for a slimmed-down version of the biotech.

AstraZeneca has penned a pact to develop bicyclic peptides with Bicycle Therapeutics.

Sanofi has assumed responsibility for Warp Drive Bio's aminoglycoside antibiotic program.

Halozyme Therapeutics has suffered a disappointment as the first phase of a $1 billion-plus collaboration with AbbVie ended in failure.

Viralytics just reported impressive data for its virus-based cancer therapy that could bring commercial partners out of the woodwork.

Bristol-Myers has teamed with Enterome to discover microbiome-derived biomarkers, drug targets and bioactive molecules relevant to its immuno-oncology team.

Roche has put together a cancer immunotherapy research network and committed up to $100 million to support collaborations between the 21 academic centers.

Stallergenes Greer and Stanford University have teamed up to look for biomarkers of peanut oral immunotherapy efficacy.

Bristol-Myers Squibb has teamed up with Johns Hopkins University to research why patients respond and develop resistance to its PD-1 drug Opdivo.